How LSD and shrooms could help treat anxiety, addiction and depression
TLDRThe script explores the potential of psilocybin, a psychedelic compound found in magic mushrooms, for medical use, particularly in addiction treatment. It features Alana's transformative experience, who quit smoking after 37 years following psilocybin treatment. Despite preliminary research and small sample sizes, studies suggest psychedelics could treat addiction, OCD, anxiety, and depression. The script also discusses the increased brain connectivity induced by LSD and the challenges of sustaining treatment benefits over time. It highlights the need for further research and funding, hindered by the inability to patent old drugs and historical backlash against psychedelics.
Takeaways
- 🍄 Alana describes her psilocybin experience as life-changing, peaceful, and transformative, despite some scary moments.
- 🤝 The psilocybin session was part of a controlled medical test, where Alana could signal for reassurance, indicating a safe and supportive environment.
- 🚭 Alana, a 37-year smoker, quit smoking after her psilocybin treatment and has not had a cigarette since, highlighting the potential of psychedelics in addiction treatment.
- 🔬 Research on psychedelics for medical use is in its preliminary stages, often with small sample sizes due to the Schedule 1 drug classification and associated restrictions.
- 📚 A review by German Lopez suggests psychedelics show promise in treating addiction, OCD, anxiety, and depression.
- 🔢 A small study showed 80% of smokers abstained from smoking for six months post-psilocybin treatment, demonstrating potential efficacy.
- 🏥 In a pilot study with terminal cancer patients, psilocybin reduced end-of-life anxiety and depression scores, indicating its potential for palliative care.
- 🧠 The increased brain connectivity during psychedelic experiences may explain both visual hallucinations and the ability to address entrenched mental health issues.
- 💡 Psychedelics seem to provide a meaningful experience that can lead to lasting changes in a patient's perspective and behavior.
- ❓ The duration of the benefits from psychedelic treatments is still uncertain, with some studies showing a decrease in benefits over time.
- ⚠️ There are risks associated with psychedelic drug use, including unpredictable reactions and potential harm to those predisposed to psychotic conditions.
- 💡 Despite the risks and limitations, there is significant potential in psychedelic research for treating debilitating disorders, warranting further investigation and funding.
Q & A
What was Alana's experience with psilocybin like?
-Alana described her experience with psilocybin as peaceful, joyous, and life-changing, despite having some scary and foreboding parts. She felt a sense of freedom and reassurance during the process.
How was Alana's psilocybin session different from typical recreational use?
-Alana's psilocybin session was part of a controlled medical test aimed at exploring the potential of psychedelics in helping people quit smoking, rather than a recreational experience.
What was the purpose of the hand-squeezing gesture during Alana's session?
-The hand-squeezing gesture served as a reassurance mechanism to help Alana feel grounded and connected to reality during her psychedelic experience.
How long had Alana been smoking before her psilocybin treatment?
-Alana had been smoking for 37 years before participating in the psilocybin treatment.
What challenges do researchers face in studying psychedelics for medical use?
-Researchers face challenges such as small sample sizes, extra regulatory hurdles due to the Schedule 1 drug classification, and difficulty in securing funding.
What conditions have psychedelics shown promise in treating according to the studies reviewed by German Lopez?
-Psychedelics have shown promise in treating addiction, OCD, anxiety, and in some cases, depression.
What was the success rate of the small study involving 15 smokers who underwent psilocybin treatment?
-In the small study of 15 smokers, 80 percent were able to abstain from smoking for six months after psilocybin treatment.
How did psilocybin affect the participants in the study involving advanced cancer patients with end-of-life anxiety?
-Participants who took psilocybin in the study generally showed lower scores on a test of depression, indicating a reduction in end-of-life anxiety.
What is one of the theories on how psychedelics might help overcome mental health issues?
-One theory is that psychedelics increase connectivity between various parts of the brain, helping to break entrenched pathological patterns and leading to lasting changes.
What is one of the remaining questions about the benefits of psychedelic treatments?
-A significant remaining question is how long the benefits of psychedelic treatments last after a one-time session.
What are some of the risks associated with using psychedelic drugs in treatment?
-Risks include unpredictable patient reactions, potential self-endangerment, and the risk of a traumatic experience for those predisposed to psychotic conditions.
Why is much of the research on psychedelics relatively new despite their long history?
-The research is relatively new because these drugs cannot be patented, reducing pharmaceutical companies' incentive to fund research. Additionally, backlash and abuse in the 50s and 60s led to a halt in research funding and cessation of studies.
Outlines
🍄 Alana's Life-Changing Psilocybin Experience
Alana recounts her profound and transformative experience with psilocybin, a naturally occurring psychedelic compound found in magic mushrooms, as part of a controlled medical test. Despite the presence of scary and foreboding parts, she found the experience to be freeing and life-changing. This was not a recreational use, but rather an attempt to help her quit smoking, a habit she had maintained for 37 years. The session involved a reassuring presence who would squeeze her hand to remind her of reality, and since the psilocybin treatment, Alana has not smoked a cigarette.
🧪 Preliminary Research on Psychedelics for Medical Use
The script discusses the preliminary nature of research into the medical use of psychedelics, such as LSD and psilocybin, which are classified as Schedule 1 drugs by the federal government, making research challenging due to additional regulations and funding scarcity. Despite these obstacles, reviewed studies by Vox writer German Lopez suggest that psychedelics show potential in treating addiction, OCD, anxiety, and depression. Specific studies are highlighted, including one where 80% of smokers abstained from smoking for six months post-treatment and another where psilocybin reduced depression scores in terminal cancer patients with end-of-life anxiety.
🧠 The Neurological Effects of Psychedelics
The script delves into the neurological effects of psychedelics, explaining that they increase connectivity between various parts of the brain, beyond just the visual cortex. This enhanced communication is believed to underlie the visual hallucinations experienced during a trip and could potentially explain the therapeutic effects of psychedelics. The idea is that psychiatric disorders may be seen as the brain being stuck in pathological patterns, and psychedelics might help by providing a meaningful or mystical experience that leads to lasting changes in a patient's perspective and behavior.
🚭 The Long-Term Benefits and Risks of Psychedelic Treatments
The discussion continues with the long-term benefits of psychedelic treatments, noting that there are still many unknowns, such as the duration of the benefits after a single treatment. Some studies have shown a lack of statistically significant benefits after 12 months for LSD-assisted psychotherapy for alcoholism, and a reduction in benefits for depression treatment after three months. The script also acknowledges the risks associated with psychedelic drug use, including unpredictable patient reactions and the potential for self-endangerment, especially for those predisposed to psychotic conditions.
💡 The Promise and Challenges of Psychedelic Research
The script concludes by emphasizing the need for further research and funding into psychedelics due to their potential in treating some of the most debilitating and costly disorders. It points out the challenges in drawing solid conclusions from existing studies and the importance of continued investigation. The historical context is provided, explaining why much of the research is new despite the long-known existence of psychedelics, due to their inability to be patented and the resulting lack of pharmaceutical company interest, as well as past backlash and funding issues.
Mindmap
Keywords
💡Psilocybin
💡Psychedelics
💡Schedule 1 drugs
💡Addiction
💡OCD
💡Anxiety
💡Depression
💡Brain connectivity
💡Psychiatric disorders
💡Pharmaceutical companies
💡Research funding
Highlights
Alana describes her psilocybin experience as life-changing, with both scary and beautiful aspects.
Psilocybin, found in magic mushrooms, was administered in a controlled medical test for smoking cessation.
Alana, a 37-year smoker, quit smoking after her psilocybin session and has not smoked since.
Medical research on psychedelics is limited by small sample sizes and federal drug scheduling.
German Lopez's review of studies indicates psychedelics' potential in treating addiction, OCD, anxiety, and depression.
A study showed 80% of smokers abstained from smoking for six months post-psilocybin treatment.
Psilocybin treatment reduced end-of-life anxiety in advanced cancer patients, as shown by lower depression scores.
Another study suggests psilocybin could help with alcohol dependence by reducing drinking days.
Psychedelics may work by providing a meaningful experience that leads to lasting brain changes.
LSD use results in increased brain connectivity, which may explain visual hallucinations and mental health benefits.
Psychiatric disorders are likened to entrenched brain pathology, with psychedelics potentially breaking harmful patterns.
Albert Garcia-Romeu discusses the remaining question of how long the benefits of psychedelic treatments last.
Some studies show a lack of significant benefits from LSD-assisted psychotherapy for alcoholism after 12 months.
Benefits of psilocybin for depression may diminish after three months, according to recent research.
There are risks associated with psychedelic drug use, including unpredictable reactions and potential harm to those with psychotic predispositions.
The need for further research and funding is emphasized, given the potential of psychedelics to treat debilitating disorders.
The lack of patentability for old drugs like psychedelics means pharmaceutical companies have little incentive to fund research.
Research into psychedelics was abundant in the 50s and 60s but ceased due to backlash and abuse concerns.
Current resurgence in psychedelic research is funded by private contributors rather than government sources.
Transcripts
Browse More Related Video
Revealing the Mind: The Promise of Psychedelics
Psychedelics: effects on the human brain and physiology | Simeon Keremedchiev | TEDxVarna
Here's Why You Want To Know About Mushrooms and Depression
The Neuroscience Behind Psychedelics with Top Neuroscientist Professor Robin Carhart-Harris
Can Magic Mushrooms Unlock Depression? | Rosalind Watts | TEDxOxford
Psilocybin Medical Trial: The Healing Mushrooms (Medical Documentary) | Real Stories
5.0 / 5 (0 votes)
Thanks for rating: